Approval for Appointment of M/s Sarang Shivajirao Chavan & Associates as the Statutory Auditor of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Bacil Pharma held a meeting on August 25, 2025 and approved two key appointments. M/s Sarang Shivajirao Chavan & Associates (FRN 159649W), an Ahmedabad-based audit firm, was appointed as the Statutory Auditor for FY 2025-2026. Separately, Mr. Vivek Mukesh Yadav (DIN: 11033957) was appointed as an Independent Director, bringing experience in finance, accounts, and corporate management. The filing was signed by Director & CFO Ms. Chaitali Kalpataru Shah. No reasons for urgency or red flags were mentioned in the disclosures.
Routine governance refresh — a new statutory auditor and an independent director have been onboarded for FY 2025-2026, which supports continued financial oversight but carries no material positive or negative signal for the stock.